Table 3.
Pharmacokinetic parameters of crizotinib in Japanese non‐small‐cell lung cancer patients with ABCB1 polymorphism
| All patients n = 8 | Significant AE n = 5 | No significant AE n = 3 | P‐value | |
|---|---|---|---|---|
| AUC0–12, ng h/mL | ||||
| Day 1 | 872 ± 379 | 1040 ± 264 | 650 ± 519 | 0.57 |
| Day 15 | 5410 ± 3220 | 6540 ± 3660 | 3940 ± 277 | 0.04 |
| Ratio | 6.20 ± 3.55 | 6.28 ± 3.75 | 6.06 ± 4.01 | |
| C max, ng/mL | ||||
| Day 1 | 129 ± 54.0 | 156 ± 49.1 | 94.6 ± 44.4 | 0.14 |
| Day 15 | 525 ± 279 | 631 ± 312 | 387 ± 28.7 | 0.04 |
| C trough on day 15 | 422 ± 302 | 512 ± 354 | 305 ± 39.3 | 0.04 |
| Half‐life, min | ||||
| Day 1 | 447 ± 522 | 528 ± 645 | 338 ± 117 | 0.25 |
| Day 15 | 2010 ± 3780 | 1840 ± 1830 | 2310 ± 6190 | 1.00 |
| T max, min | ||||
| Day 1 | 304 ± 86.8 | 323 ± 97.8 | 275 ± 67.0 | 0.57 |
| Day 15 | 268 ± 198 | 245 ± 246 | 310 ± 68.9 | 0.79 |
AE, adverse event; AUC0–12, area under the plasma concentration–time curve from 0 to 12 h; C max, peak concentration; C trough, trough concentration; T max, time to maximum concentration.